E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

Phase 2TerminatedNCT01355302

Eisai Inc.7 enrolled

Overview

The purpose of this study is to determine the following: 1. Find the maximum tolerated dose of E7050 when given in combination with cisplatin and capecitabine in patients with advance or metastatic solid tumors, and 2) Whether E7050 in combination with cisplatin and capecitabine is more effective in patients with previously untreated gastric cancer versus cisplatin and capecitabine alone.

This open-label, multicenter, randomized study will consist of 2 phases: Phase Ib: a safety run-in period with 3 ascending doses of E7050 in combination with fixed doses of Cisplatin and Capecitabine. This phase will enroll approximately 10 to 15 patients. * Phase II: a randomized 2-arm design which will enroll 80 patients. In the phase II portion, Patients will receive study treatment , E7050 in combination with Cisplatin and Capecitabine versus Cisplatin and Capecitabine Alone) for approximately six 21-day cycles (18 weeks). Beyond 18 weeks, patients who are experiencing clinical benefit may continue E7050, with or without Capecitabine (Arm 1), or may continue Capecitabine alone (Arm 2), depending on the original randomization treatment arm. Patients will continue treatment for as long as clinical benefit is sustained and the treatment is well tolerated, until the occurrence of progressive disease (PD), unacceptable toxicity, withdrawal of consent, or withdrawal by investigator, whichever occurs first. Patients will participate in either phase Ib or phase II.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Advanced or Metastatic Solid Tumors

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria * Histologically confirmed, unresectable, locally advanced or metastatic gastric cancer, including adenocarcinoma of the gastroesophageal junction (Phase II). For the Phase Ib portion, any unresectable, locally advanced or metastatic solid tumor; * ECOG PS of 0-1; * Blood pressure must be well-controlled. Patients must have no history of hypertensive crisis or hypertensive encephalopathy; Adequate end organ function Exclusion Criteria * Gastric cancer patients who have had a complete gastrectomy; * Patients with known HER2 over-expressing advanced or metastatic gastric cancer; * Previously received E7050, its chemical derivatives, anti-cMet, anti-angiogenic therapy, (prior anti-angiogenic therapy is permitted in Phase Ib only). * For Phase Ib prior systemic therapy is allowed as long as PS and end organ function meet entry criteria; * For Phase II no prior palliative chemotherapy is permitted. Adjuvant/neoadjuvant chemotherapy is permitted if less than 12 months have elapsed between the end of adjuvant/neoadjuvant therapy and first recurrence; * Known central nervous system lesions, except for asymptomatic non-progressing, treated brain metastases. Treatment for brain mets, but have been completed at least 4 weeks prior to Day 1 * Palliative radiotherapy is not permitted throughout the study period. Prior palliative radiotherapy within 30 days prior to commencing study treatment; * Clinically significant hemoptysis; * Patients with known dihydropyrimidine dehydrogenase deficiency; * Patients with clinically significant hearing loss that may be further diminished by treatment with cisplatin plus capecitabine (significance of hearing loss to be determined by the Investigator; * Serious non-healing wound, ulcer, or active bone fracture; * Major surgical procedure, open biopsy, or significant traumatic injury within the 21 days prior to commencing study treatment; * Clinically significant gastrointestinal bleeding within 6 months prior to first dose.

Locations (19)

Arizona Oncology Associates, PC - CASA

Tucson, Arizona, United States

Boca Raton Clinical Research Associates, Inc

Plantation, Florida, United States

Robert H. Lurie Comprenhensive Cancer Center of Northwestern University

Chicago, Illinois, United States

University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, United States

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, United States

Henry Ford Medical Center

Detroit, Michigan, United States

University of North Carolina at Chapel Hill

Chapell Hill, North Carolina, United States

Duke University Medical Center

Durham, North Carolina, United States

Mercy Cancer Centerr at St. Anne

Toledo, Ohio, United States

Chelyabinsk Regional Oncology Dispensary

Chelyabinsk, Russia

...and 9 more locations

Outcomes

Primary Outcomes

Area Under The Concentration-Time Curve (AUC) From 0 to 24 Hours of Golvatinib

On days when pharmacokinetic (PK) samples were to be drawn, a predose blood sample was obtained prior to administration of golvatinib and capecitabine. After administration of study drugs, a second postdose blood sample was taken. The amount of golvatinib in the participant's blood was analyzed and the AUC was calculated. The AUC reflects the actual body exposure to drug after administration of a dose of the drug and is dependent on the rate of elimination of the drug from the body and the dose administered. Predose samples that were below the limit of quantitation (BLQ) or missing were assigned a numerical value of zero for the calculation of AUC. Any other BLQ concentrations were assigned a value of zero. Results were expressed in nanograms·hour/milliter (ng·h/mL).

Time frame: Cycle 1 (Day -2); predose, 30 minutes, 1, 2, 3, 4, 8, 12 (if feasible), 24, and 48 hours after study treatment. Cycle 2 (Day 1); predose, 30 minutes, 1, 2, 3, 4, 8, 12 (if feasible), and 24 hours after study treatment.

Maximum Concentration (Cmax) of Golvatinib

Blood samples were drawn to analyze the amount of golvatinib in the participant's serum. Maximum concentration refers to the maximum (or peak) serum concentration of study drug in the participant's system after administration of the study drug and prior to the administration of a second dose of the study drug. Results were expressed in nanograms/milliliter (ng/mL).

Number of Participants With a Treatment-Emergent Adverse Event (TEAE)

Safety assessments consisted of monitoring and recording all adverse events (AEs) and serious AEs; regular monitoring of hematology, blood chemistry, and urine values; periodic measurement of vital signs and electrocardiograms (ECGs); and performance of physical examinations. A TEAE was defined as an adverse event (AE) that had an onset date, or a worsening in severity from Baseline (pretreatment), on or after the first dose of study drug up to 30 days after the date of last study treatment.

Time frame: From date of first dose up to 30 days after the last dose of study treatment, up to approximately 1 year 1 month.

Time to Maximum Concentration (Tmax) of Golvatinib

Tmax was defined as the time at which Cmax was observed for golvatinib in combination with cisplatin and capecitabine.

Secondary Outcomes

Overall Response Rate (ORR)

The study was terminated prior to enrollment in Phase 2 so this outcome measure was not conducted.

Time frame: Until disease progression or death for 3 years

Time to Progression (TTP)